Current Research Studies
Phase 3, multicenter, randomized, double-blind, group sequential, placebo-controlled study to assess efficacy and safety of rimegepant for the treatment of migraine (with or without aura) in children and adolescents ? 6 to < 18 years of age
Rimegepant 311
What is the goal of the study?
To evaluate the efficacy of rimegepant compared with placebo in the acute treatment of migraine in adolescent population (? 12 to < 18 years of age) as measured by pain freedom at two hours post-dose.
Who can participate in the study?
Please contact the study team listed below to learn more.